Evidence map›Paper›PMID 34368897›Full record

ArticleNeuroradiology2022

Radiomics-based MRI for predicting Erythropoietin-producing hepatocellular receptor A2 expression and tumor grade in brain diffuse gliomas.

Xiaoxue Liu, Jianrui Li, Xiang Liao, Zhongqiang Luo, Qiang Xu, Hao Pan, Qing Zhou, Yan Tao, Feng Shi, Guangming Lu and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Neuroradiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Xiaoxue LiuDepartment of Diagnostic Radiology, Affiliated Jinling Hospital, Medical School of Nanjing University, 305#, Eastern Zhongshan Rd, Nanjing, 210002, China.
Jianrui LiDepartment of Diagnostic Radiology, Affiliated Jinling Hospital, Medical School of Nanjing University, 305#, Eastern Zhongshan Rd, Nanjing, 210002, China.
Xiang LiaoDepartment of Diagnostic Radiology, Affiliated Jinling Hospital, Medical School of Nanjing University, 305#, Eastern Zhongshan Rd, Nanjing, 210002, China.
Zhongqiang LuoDepartment of Diagnostic Radiology, Affiliated Jinling Hospital, Medical School of Nanjing University, 305#, Eastern Zhongshan Rd, Nanjing, 210002, China.
Qiang XuDepartment of Diagnostic Radiology, Affiliated Jinling Hospital, Medical School of Nanjing University, 305#, Eastern Zhongshan Rd, Nanjing, 210002, China.
Hao PanDepartment of Neurosurgery, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, 210002, China.
Qing ZhouDepartment of Research and Development, Shanghai United Imaging Intelligence Co., Ltd, Shanghai, 200232, China.
Yan TaoDepartment of Research and Development, Shanghai United Imaging Intelligence Co., Ltd, Shanghai, 200232, China.
Feng ShiDepartment of Research and Development, Shanghai United Imaging Intelligence Co., Ltd, Shanghai, 200232, China.
Guangming LuDepartment of Diagnostic Radiology, Affiliated Jinling Hospital, Medical School of Nanjing University, 305#, Eastern Zhongshan Rd, Nanjing, 210002, China.
Zhiqiang ZhangDepartment of Diagnostic Radiology, Affiliated Jinling Hospital, Medical School of Nanjing University, 305#, Eastern Zhongshan Rd, Nanjing, 210002, China. zhangzq2001@126.com.ORCID http://orcid.org/0000-0001-6989-9550
Nanjing General Hospital of Nanjing Military Command · CNUnited Imaging Healthcare (China) · CNNanjing University · CN

Funding

grants of the key talent project in Jiangsu province ZDRCA2016093health system strengthening project with Science and Education of Jiangsu provincial Commission of Health and Family Planning YXZXA2016007Natural Science Foundation of China 81530054Natural Science Foundation of China 81830056Natural scientific foundation-social development BE2016751Post-doctoral grants of China 2016M603064Post-doctoral grants of Jiangsu Province 1501169Bthe National Key Technology (R&D) Program of the Ministry of Science and Technology 2018YFA0701703
6 · The paper itself

Abstract

purposeEphA2 is a key factor underlying invasive propensity of gliomas, and is associated with poor prognosis of tumors. We aimed to develop a radiomics-based imaging index for predicting EphA2 expression in diffuse gliomas, and further estimating its value for grading of tumors.

methodsA total of 182 patients with diffuse gliomas were included. All subjects underwent pre-operative MRI and post-operative pathological diagnosis. EphA2 expression of tumors was scored on pathological sections with immunohistochemical staining using monoclonal EphA2 antibody. MRI radiomics features were extracted from three-dimensional contrast-enhanced T1-weighted imaging and diffusion kurtosis imaging. Predictive models were constructed using machine learning-based radiomics features selection and three classifiers for predicting EphA2 expression and tumor grade. Features of best EphA2 expression model were subsequently used to construct another model of tumor grading. For each model, 146 cases (80%) were randomly picked as training and the rest 36 (20%) were testing cohorts. EphA2 expression was further correlated to the radiomics features in both grade models using Spearman's correlation.

resultsLogistic regression model presented highest performance for predicting EphA2 expression (AUC: 0.836/0.724 in training/validation set). Tumor gradings model guided by features from EphA2 expression model demonstrated comparable performance (AUC: 0.930/0.983) to that constructed directly using imaging radiomics features (AUC: 0.960/0.977). Two radiomics features which included in both LR-grade models showed strong correlation (P < 0.05) with EphA2 expression.

conclusionThe expression of EphA2 in gliomas could be predicted by radiomics features extracted from diffusion kurtosis MRI, which could also be used to assist tumor grading.

Indexed as

Brain NeoplasmsCarcinoma, HepatocellularErythropoietinGliomaLiver NeoplasmsBrainHumansMagnetic Resonance ImagingReceptors, ErythropoietinRetrospective StudiesErythropoietinReceptors, ErythropoietinDiffusion kurtosis imagingEphA2GliomaNeoplasm gradingRadiomics

Identifiers

PMID34368897
OpenAlexW3190133519

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.